Keros Therapeutics (NASDAQ:KROS) Posts Earnings Results, Misses Estimates By $0.37 EPS

Keros Therapeutics (NASDAQ:KROS) announced its quarterly earnings results on Wednesday. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.37), FiscalAI reports. Keros Therapeutics had a net margin of 26.12% and a return on equity of 9.51%. The company had revenue of $0.39 million during the quarter, compared to analyst estimates of $3.66 million. During the same quarter in the prior year, the company posted ($1.14) earnings per share. The firm’s revenue for the quarter was down 87.2% on a year-over-year basis.

Keros Therapeutics Stock Up 2.8%

Keros Therapeutics stock opened at $13.77 on Thursday. The business has a 50 day moving average price of $17.81 and a two-hundred day moving average price of $17.10. The stock has a market cap of $419.57 million, a price-to-earnings ratio of 8.94 and a beta of 0.87. Keros Therapeutics has a 12 month low of $9.12 and a 12 month high of $22.55.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on KROS. Oppenheimer reaffirmed an “outperform” rating and set a $27.00 price target (up from $23.00) on shares of Keros Therapeutics in a research report on Wednesday, November 12th. TD Cowen upgraded Keros Therapeutics to a “hold” rating in a research note on Friday, December 19th. Zacks Research downgraded Keros Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 1st. Bank of America boosted their price target on Keros Therapeutics from $18.00 to $19.00 and gave the company a “neutral” rating in a report on Friday, November 28th. Finally, Wedbush upped their price target on Keros Therapeutics from $15.00 to $16.00 and gave the company a “neutral” rating in a research report on Thursday, November 6th. Five analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Keros Therapeutics has a consensus rating of “Hold” and a consensus target price of $22.29.

Hedge Funds Weigh In On Keros Therapeutics

A number of hedge funds have recently modified their holdings of KROS. Renaissance Technologies LLC grew its holdings in Keros Therapeutics by 282.5% during the 4th quarter. Renaissance Technologies LLC now owns 591,686 shares of the company’s stock worth $12,047,000 after acquiring an additional 436,986 shares during the last quarter. Canada Pension Plan Investment Board bought a new position in shares of Keros Therapeutics in the second quarter worth about $4,251,000. Caption Management LLC lifted its position in shares of Keros Therapeutics by 114.1% during the second quarter. Caption Management LLC now owns 36,078 shares of the company’s stock worth $482,000 after purchasing an additional 291,997 shares in the last quarter. Qube Research & Technologies Ltd grew its stake in shares of Keros Therapeutics by 683.7% during the third quarter. Qube Research & Technologies Ltd now owns 303,122 shares of the company’s stock valued at $4,795,000 after purchasing an additional 264,445 shares during the last quarter. Finally, Weiss Asset Management LP acquired a new stake in shares of Keros Therapeutics in the fourth quarter valued at approximately $5,173,000. 71.56% of the stock is owned by institutional investors and hedge funds.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.